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response. 69.2% in the RT + CON group had a complete response.
90.9% of the CRT + CON group and 63.6% of the CRT group had a
complete response (statistically significant at p = 0.031). No signif-
icant correlation was found between RT + CON and CRT
(p = 0.313).
Interpretation: This study shows that hypoxia and cell prolifer-
ation increase with tumour volume. The response to radiation
increased significantly in the group who received CON as part of
treatment. This finding shows that CON has an important role
in breaking the cycle that causes radio-chemoresistance. There-
fore, CON in combination with RT can be considered for those
who are not eligible for or refuse chemotherapy.
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Background: Nischarin, a novel protein, was originally identi-
fied as an a5b1 interacting protein and has been shown to inhibit
cell motility through inhibition of the Rac/PAK/LIMK/Coffinin
pathway. Nischarin blocks tumour-cell migration and invasion
in breast-cancer cell line MCF7.
Methods: To further study the role of Nischarin in breast can-
cer, we evaluated expression levels by immunohistochemistry
in 36 breast-cancer and 20 normal-breast tissue sections. We
also looked at the expression pattern using the NCBI-GEO
database.
Findings: Nischarin expression was positive in 27.8% (10/36)
breast-cancer tissues, which was significantly lower than the per-
cent expressing the protein in normal breast tissues (55%, 11/20;
p < 0.05). Furthermore, expression of Nischarin in breast cancer
was associated with oestrogen-receptor (ER) status. Nischarin
was expressed in 60% (6/10) ER-positive tumour tissues, whereas
in ER-negative tumour tissues, positivity of Nischarin was only
15.4% (4/26; p < 0.05). Concordant with immunostaining, NCBI-
GEO analysis confirmed that Nischarin was poorly expressed in
HER2-positive and/or ER-negative highly invasive breast cancer,
and was expressed at higher levels in other cancerous cells and
in normal breast tissue.
Interpretation: These data suggest that Nischarin has an
important role in breast-cancer progression, and it might be a
potential tumour suppressor. The relationship between Nischa-
rin and breast cancer, and the mechanism, are currently being
studied.
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